Articles tagged with Immunotherapy
Researchers identified a compound that promotes a vigorous immune assault against pancreatic tumors, significantly shrinking them and improving survival. The compound, ADH-503, shifts the balance of myeloid cells toward those that activate T cells to attack cancer, making resistant cancers susceptible to immunotherapy.
A new clinical trial shows that immunotherapy pembrolizumab is more effective than standard aggressive chemotherapy in treating people with recurrent head and neck cancer. The combination of pembrolizumab with platinum chemotherapy extended survival by 3.7 months, while the immunotherapy alone showed improved survival rates compared to...
A new test developed by UT Southwestern Medical Center aims to identify kidney cancer patients most likely to benefit from immunotherapy. The test uses a diagnostic tracer to visualize tumors and assess PD-L1 expression, which can predict treatment response. The approach has shown promise in early studies.
The combination immunotherapy of nivolumab and ipilimumab met the primary endpoint of the NEOSTAR trial with a 33% overall major pathologic response rate in early-stage lung cancer patients. The treatment was also shown to be effective in reducing tumor viability, with six out of 21 patients achieving a complete pathological response.
Researchers discover parvifoline AA, a natural compound, stimulates NKG2D ligands on cancer cells, making them more recognizable and targetable by NK cells. This increases the effectiveness of NK cell-based tumor immunotherapy.
Researchers found that tumor mutation score is associated with responses to immunotherapy in metastatic colorectal cancer patients. Patients with high mutation scores are more likely to respond to immunotherapy, while those with low scores may benefit from chemotherapy.
Researchers at the University of Navarra found that pretreating patients with TNF inhibitors before combining immunotherapy can reduce adverse effects and improve treatment response in animal models. The study suggests a new approach to treating cancer by blocking tumor necrosis factor while applying combination immunotherapy.
Researchers found that MSI intensity and mutational load significantly impact MMR-deficient tumors' response to PD-1 therapy. Higher mutational loads result in better responses to treatment.
Researchers found a new pathway to killing cancer cells by targeting ferroptosis, a type of cell death linked to immune cells. The study suggests that combining ferroptosis sensitizer and checkpoint inhibitor treatments creates a strong immune response that fights tumors.
A systematic review of 12 studies with over 1,000 patients found that peanut oral immunotherapy increases the risk and frequency of anaphylaxis and allergic reactions. Despite inducing desensitisation in the clinic, the treatment does not lead to improved quality of life for patients.
A new study published in the Journal of Allergy and Clinical Immunology: In Practice suggests that oral immunotherapy is safe for preschool-aged children with peanut allergies. Researchers followed 270 children who received oral immunotherapy and found that 90% reached the maintenance stage successfully.
Researchers discovered that cancer cells can hide from immunotherapy by altering the levels of a key molecule on their surface. However, they identified an existing inhibitor of the WNT pathway that could potentially reverse this process and make cancer cells more visible to immune cells.
The CheckMate 451 study found that maintenance immunotherapy did not prolong overall survival in patients with extensive-stage small cell lung cancer. However, the study suggested that patients who received early maintenance therapy may have longer progression-free survival rates.
Researchers map the landscape of myeloid cells in lung cancer tumors using single-cell sequencing, revealing 25 distinct subpopulations with consistent gene expression signatures across patients. The findings provide a powerful starting point to better understand their functions and clinical applications.
New studies provide insights into the efficacy and safety of immunotherapy in elderly patients with advanced non-small-cell lung cancer. Real-life studies suggest that elderly patients may have shorter overall survival but similar toxicity rates compared to younger patients.
A University of Colorado Cancer Center study identifies a possible way to predict which melanomas are hot and cold for immunotherapy. Tumors with specific genetic changes in the NF-kB signaling pathway are more likely to respond to anti-PD1 immunotherapies, suggesting a potential biomarker for treatment prediction.
A study suggests that increasing T cells' exposure to potassium, mimicking high potassium levels, could make cancer immunotherapies more effective. Growing T cells under conditions of high potassium preserves their stem-cell-like quality, allowing them to replicate and grow.
PET/CT scans can monitor immunotherapy treatment for metastatic melanoma and predict outcome, allowing personalized therapy adjustments. The study demonstrates that FDG PET/CT can accurately assess tumor response to checkpoint inhibitor therapy with ipilimumab.
A multi-year observational study found that eating small amounts of peanut after immunotherapy can extend allergy treatment benefits and improve quality of life. The majority of participants continued regularly eating peanuts daily for up to eight years without any reactions from accidental ingestions.
A study by Cedars-Sinai Medical Center has identified a drug called dasatinib that could enhance the effectiveness of immunotherapies for various types of cancers. The researchers found that combining dasatinib with anti-PD-1 therapy increased sensitivity in cancer cells, making it a promising approach to improve treatment outcomes.
Researchers at the University of Helsinki found that allergen immunotherapy reduces symptom scores and alters nasal epithelial transcriptome in patients with allergic rhinitis. The study also showed improved diversity of the nasal microbiome in response to treatment.
Researchers found a promising new treatment for small cell lung cancer by combining immune checkpoint blockade with targeted therapies that block DNA damage repair. This combination achieved significant tumor regression in mouse models, suggesting potential benefits for patients.
Research reveals that patients with specific MAPK mutations are more likely to respond to immunotherapy drugs in glioblastoma. The study also found that tumors with PTEN mutations were less responsive to treatment, suggesting new targets for treatment development.
Researchers have identified a new target protein that can inhibit Mycobacterium tuberculosis-induced cell death. Corticosteroids, already used in tuberculosis treatment, may support the healing process by inhibiting this pathway. This immunotherapy approach could reduce treatment duration and secondary complications associated with TB.
Researchers found that eliminating protein YTHDF1 boosts dendritic cell activity, leading to better immune response against cancer. This discovery opens new avenues for cancer treatment and may lead to effective combination therapies with checkpoint inhibitors or dendritic cell vaccines.
Research finds that plerixafor reduces fibrosis and improves response to immunotherapy in mouse models of metastatic breast cancer. Fibrosis blocks effectiveness of immunotherapies, but CXCR4 inhibition enhances immune cell infiltration and decreases formation of spontaneous metastases.
The iReceptor Plus consortium, led by Bar-Ilan University, aims to develop an innovative platform for integrating distributed genomic datasets to improve personalized medicine and immunotherapy in various diseases.
Researchers found that many slow-growing NF1 gliomas contain few macrophages and produce proteins that can trigger an immune system attack, making them good candidates for treatment with immunotherapy. Clinical trials are now being planned for these high-immune tumors.
Researchers reported promising early results from a clinical study of genetically engineered immune cells that recognize and fight cancer cells. The treatment generated excellent responses when used after chemotherapy, with 71% of patients achieving complete response.
A clinical trial led by CNIO's Luis Paz-Ares showed that immunotherapy significantly increases patient survival when administered alongside conventional chemotherapy. This opens the door to investigate its effectiveness in early stages of the disease.
A UCalgary research team analyzed publicly accessible health and genomics data to identify a gene signature that can help determine which cancer patients will benefit from immunotherapy. This discovery has the potential to improve treatment outcomes for these patients.
A new treatment has been shown to help people with peanut allergies build up a tolerance to the allergen, allowing them to consume small amounts without experiencing severe reactions. The study found that two-thirds of participants were able to tolerate the equivalent of two peanuts per day after nine to 12 months of treatment.
Cornelis Melief is recognized for his life's work in studying the interactions of the immune system with cancer, leading to the development of new therapeutic cancer vaccine strategies. His research has shown clinical effectiveness in treating patients with pre-malignant lesions caused by HPV type 16.
Navin Varadarajan is modifying T cells to recognize and kill glypican-3, a molecule found in liver cancer cells. The goal is to develop an effective treatment for high-risk pediatric liver cancer with poor survival rates.
Researchers at UT Southwestern Medical Center have identified blood-based biomarkers that may help identify patients at greatest risk of developing autoimmune side effects from immunotherapy. The study found that levels of certain cytokines were particularly low before treatment in patients who developed immune-related adverse events.
Researchers at Mount Sinai Hospital have successfully induced desensitization in the majority of children with wheat allergies through oral immunotherapy. After 52 weeks, 52% of children consumed a cumulative dose of 4,443mg of wheat protein without adverse reactions.
Researchers at the University of Notre Dame have found a way to inhibit T-cell activation by targeting nitration of an amino acid in cancer cells. This approach could enhance cancer immunotherapy by identifying activity-based markers and designing approaches that shut down specific mechanisms inhibiting T-cell activation.
Researchers developed a nanofluidic seed that can deliver sustained-release doses of immunotherapy directly to tumors, reducing the need for multiple IV treatments and eliminating side effects. The device has shown promising results in mice models, with equal effectiveness compared to systemic immunotherapy while minimizing toxicities.
A phase III clinical trial found immunotherapy pembrolizumab to be more effective than aggressive chemotherapy as a first-line treatment for advanced head and neck cancer. Patients with high PD-L1 levels saw significant improvements in survival and response rates.
A study suggests that immunotherapy is safe and feasible for HIV-positive cancer patients. The treatment appears to be well-tolerated as long as antiretroviral therapy is continued in parallel, the key finding of the study.
A team of researchers at TUM and Helmholtz Zentrum München investigated the processes taking place in the body during a three-year allergen-specific immunotherapy. They found that regulatory B-cells play a more important role than previously thought, and that certain ratios of cell types can predict treatment success.
Researchers at CytoReason used machine learning to analyze melanoma biopsies, identifying adipocytes as potential regulators of the tumor microenvironment. The study suggests that these cells may play a previously unreported role in differentiating nivolumab responders from non-responders in ipilimumab-resistant patients.
Researchers found that immunotherapy is effective in treating metastatic melanoma in individuals with CDKN2A mutations, with nearly two-thirds of patients responding to treatment. The study suggests that tumours with CDKN2A mutations have a larger number of mutations, making them easier to recognise by the immune system.
A new DNA vaccine targeting the human MAGE-A family of proteins has shown promise in a pre-clinical model of melanoma, inducing a robust immune response and antitumor activity. The vaccine simultaneously targets multiple tumor antigens, overcoming a difficult issue in cancer immunotherapy.
A subpopulation of PD-1-expressing NK cells within tumors responds to checkpoint blockade, activating anti-cancer effects. These cells contribute significantly to the efficacy of checkpoint-targeting immunotherapies, suggesting new strategies for improving treatment outcomes.
Researchers develop radiomic signature to predict efficacy of immunotherapy in patients with solid tumors. The algorithm analyzes CT scan images to extract biological information, providing a predictive score for treatment effectiveness.
A clinical trial found that combination immunotherapy reduced melanoma brain metastases by 26% in 94 patients. The treatment, combining checkpoint inhibitors ipilimumab and nivolumab, also showed durable responses with 59.5% of patients remaining progression-free at nine months.
A simple blood test identifying patients unlikely to benefit from immunotherapy for bladder cancer could save months of unnecessary treatment. The test measures pro-inflammatory molecule Interleukin-2 release from immune cells before therapy and correctly predicted therapy outcome in almost 80% of cases.
Johns Hopkins researchers developed a new method to analyze bioinformatics data and determine how a patient's immune system responds to immunotherapy. The FEST analysis technique can be used to create a database associating immunotherapy-related responses with clinical benefits.
Researchers found a gene that recruits immune cells in alopecia areata, an autoimmune disease causing hair loss. They discovered this gene is turned off in various cancers, protecting them from the immune system. By turning it back on, tumors can be made vulnerable to immunotherapy.
Checkpoint inhibitors improve median and four-year overall survival rates for melanoma brain metastasis patients by 1.4- and 1.5-fold, respectively, according to a national cohort study published in Cancer Immunology Research.
Researchers discover DNA methylation marker that influences PD-L1 expression on cancer cells, shedding light on why new therapies don't work for some patients. The findings suggest epigenetic therapies could be used in combination with immunotherapy to treat melanoma patients.
A study investigating combination checkpoint immunotherapy in lethal advanced prostate cancer revealed that genetic subsets of patients with AR-V7+ prostate cancer may benefit from treatment. One-quarter of patients achieved an objective response, and at least two remain alive for over 18 months.
UCSF researchers identified a critical immune cell pathway that primes the immune system for effective response to checkpoint inhibitors. The presence of specific immune cells, such as dendritic cells and natural killer cells, in tumors predicts improved response to immunotherapy and overall survival. These findings enable clinicians t...
A University of Colorado Cancer Center study shows that combining radiosurgery with immunotherapy, especially PD-1 inhibitors, can significantly improve cancer control and overall survival in melanoma patients. The study found that patients treated with anti-PD-1 therapies had a median brain metastasis-free survival of not reached, whe...
Researchers have demonstrated that combining targeted radionuclide therapy with immunotherapy can enhance treatment response and lead to a high cure rate in melanoma patients. This novel approach uses yttrium-86 (Y-86) NM600, which selectively targets tumors and delivers precise radiation doses.
A new study found that a pattern of genetic changes in prostate tumours can predict which men are likely to benefit from immunotherapy. The research identified a distinct group of men with advanced prostate cancer whose tumours have biological features that make them responsive to immunotherapy drugs.
A new method for predicting treatment success in cancer patients using immunotherapy has been discovered. This method relies on a protein called PD-1, which is found on the surface of human immune cells and allows them to detect tumors more effectively.
A novel immunotherapy treatment combining a molecule expressed by cancer cells with Listeria monocytogenes has shown promising results in clinical trials for dogs with osteosarcoma. The vaccine supplements standard treatment and has been shown to improve survival times, with median survival of 956 days compared to 423 days.
Researchers found that using nanoparticles to bind molecules can trigger immune cells more effectively against cancer in laboratory studies. The combination of two therapeutics on a single nanoparticle showed higher rates of T-cell stimulation and tumor attack than separate deliveries.